Chugai’s Reduced Tamiflu Sales, Fallout From Sanofi-Aventis Deal Attribute To 35% Earnings Drop
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Chugai attributed the 35 percent revenue decrease since January to reduced sales of influenza drug Tamiflu and the dissolving of its marketing arrangement with Sanofi-Aventis. Other negative factors affecting sales were the lowering of the price for recombinant human erythropoietin, Epogin, and reduced royalty and milestone income
You may also be interested in...
U.S. FDA Advisory Committee Gives Thumbs Up To Chugai’s Actemra RA Treatment
TOKYO - The U.S. FDA's Arthritis Advisory Committee voted 10 to one for approving Actemra (tocilizumab) a rheumatoid arthritis treatment that Japan's Chugai Pharmaceutical already is marketing for Castleman's disease, Chugai and partner Roche announced July 30
Roche Partnership With Chugai Fuels Actemra Approvals In Japan, Sets Stage For U.S. And EU – Chugai Exec
SINGAPORE - Chugai attributes the success of its development program for the novel interleukin-6 receptor-inhibiting Actemra (tocilizumab) to its partnership with Roche, Chugai Business Development General Manager Kimio Nishimura told Biomedical Asia 2008 attendees in Singapore April 16
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).